SAN Sanofi

By Dominic Chopping

Sanofi SA on Thursday upgraded its full-year guidance after posting higher second-quarter sales, driven by best-selling eczema drug Dupixent.

The French pharma major posted net profit of 1.18 billion euros ($1.2 billion) for the quarter, down slightly from EUR1.2 billion the year prior. Sales rose 16% to EUR10.12 billion, from EUR8.74 billion.

Best-selling Dupixent alone grew by 43% on year to EUR1.96 billion, the company said, driving sales in Sanofi's specialty-care business. Vaccine sales grew 8.7% while general medicines saw 6.0% growth.

Business net income--a key profit metric that excludes some items--rose to EUR2.17 billion, from EUR1.73 billion the year prior, Sanofi said. Business earnings per share were EUR1.73, up 25% on the year, the company said.

Looking ahead, Sanofi said it now expects 2022 business EPS to grow by approximately 15% at constant exchange rates, having previously guided for low-double-digit growth. A full-year positive currency impact of between 7.5% and 8.5% is now expected, from between 4% and 5% previously, it added.

Write to Dominic Chopping at dominic.chopping@wsj.com

(END) Dow Jones Newswires

July 28, 2022 01:50 ET (05:50 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.